Sanofi to Present the Data from P-III Study of Dupixent at 2022 AAAAI Annual Meeting for the Treatment of Eosinophilic Esophagitis
Shots:
- Positive detailed results from a second P-III trial of Dupixent (dupilumab-300 mg, Q1W), showed the significant improvement in signs and symptoms of EoE at 24 wks. vs. to PBO in patients aged ≥12 yrs. In 2022, regulatory filings are planned in the US and other countries
- Results showed the reduction of 64% vs. 41% in disease symptoms from baseline, DSQ improvement is 23.78 vs. 13.86 point & 59% vs. 6% of patients achieved histological disease remission
- In Sep 2020, Dupixent received BTD from the U.S. FDA for the treatment of patients aged ≥12yrs. with EoE and ODD in 2017 for the treatment of EoE
Ref: Globe Newswire | Image: Sanofi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
